Jump to content
RemedySpot.com

Graham, FDA, contact information via Sen. Grassley

Rate this topic


Guest guest

Recommended Posts

Senate Finance Committee -- Vioxx Health Risks

Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient

Safety First? "

Witnesses: Lester Crawford, acting commissioner, Food and Drug

Administration (FDA) Graham, associate director for science,

Office of Drug Safety, Center for Drug Evaluation and Research, FDA;

Gurkirpal Singh, adjunct clinical professor of medicine, Division of

Gastroenterology and Hepatology, Department of Medicine, Stanford

University School of Medicine; Bruce Psaty, professor of medicine and

epidemiology, University of Washington, Cardiovascular Health

Research Unit; Gilmartin, chairman/president/CEO, Merck & Co.

Inc., Whitehouse Station, N.J.

Location: 215 Dirksen Senate Office Building. 10 a.m.

Contact: 202-224-4515

http://finance.senate.gov/

Link to comment
Share on other sites

Senate Finance Committee -- Vioxx Health Risks

Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient

Safety First? "

Witnesses: Lester Crawford, acting commissioner, Food and Drug

Administration (FDA) Graham, associate director for science,

Office of Drug Safety, Center for Drug Evaluation and Research, FDA;

Gurkirpal Singh, adjunct clinical professor of medicine, Division of

Gastroenterology and Hepatology, Department of Medicine, Stanford

University School of Medicine; Bruce Psaty, professor of medicine and

epidemiology, University of Washington, Cardiovascular Health

Research Unit; Gilmartin, chairman/president/CEO, Merck & Co.

Inc., Whitehouse Station, N.J.

Location: 215 Dirksen Senate Office Building. 10 a.m.

Contact: 202-224-4515

http://finance.senate.gov/

Link to comment
Share on other sites

Senate Finance Committee -- Vioxx Health Risks

Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient

Safety First? "

Witnesses: Lester Crawford, acting commissioner, Food and Drug

Administration (FDA) Graham, associate director for science,

Office of Drug Safety, Center for Drug Evaluation and Research, FDA;

Gurkirpal Singh, adjunct clinical professor of medicine, Division of

Gastroenterology and Hepatology, Department of Medicine, Stanford

University School of Medicine; Bruce Psaty, professor of medicine and

epidemiology, University of Washington, Cardiovascular Health

Research Unit; Gilmartin, chairman/president/CEO, Merck & Co.

Inc., Whitehouse Station, N.J.

Location: 215 Dirksen Senate Office Building. 10 a.m.

Contact: 202-224-4515

http://finance.senate.gov/

Link to comment
Share on other sites

Senate Finance Committee -- Vioxx Health Risks

Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient

Safety First? "

Witnesses: Lester Crawford, acting commissioner, Food and Drug

Administration (FDA) Graham, associate director for science,

Office of Drug Safety, Center for Drug Evaluation and Research, FDA;

Gurkirpal Singh, adjunct clinical professor of medicine, Division of

Gastroenterology and Hepatology, Department of Medicine, Stanford

University School of Medicine; Bruce Psaty, professor of medicine and

epidemiology, University of Washington, Cardiovascular Health

Research Unit; Gilmartin, chairman/president/CEO, Merck & Co.

Inc., Whitehouse Station, N.J.

Location: 215 Dirksen Senate Office Building. 10 a.m.

Contact: 202-224-4515

http://finance.senate.gov/

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...